Efavirenz treatments benefit children who have HIV
The study involved children who had achieved viral suppression with their HIV infections and confirmed that one efavirenz-based treatment could help the children without any viral failure risk.
Using these pediatric antiretroviral treatment programs has benefited children in sub-Saharan Africa with a notable decrease in mortality and morbidity with children who have HIV infections. The treatment programs are able to shift the patients to a chronic condition out of a rapidly fatal disease situation.
"There is little guidance available as to what clinicians ought to do when confronted with a child older than 3 years who has begun treatment with ritonavir-boosted lopinavir,” the study authors wrote. “As a result, it has been left to individual interpretation, and there are anecdotal reports of clinicians switching to efavirenz in the absence of data to support such a practice. This study provides evidence to support the safety and efficacy of switching to efavirenz, the recommended drug for children older than 3 years, among children with viral suppression.”